ITUS Extends and Expands Collaborative Research Arrangement With The Wistar Institute

LOS ANGELES, CA -- (Marketwired) -- 08/15/16 -- ITUS Corporation (NASDAQ: ITUS) today announced that it has extended and expanded its collaboration with The Wistar Institute to further the development of Cchek™, the company's early cancer detection platform. The company is extending its existing arrangement with Wistar, and entering into a new collaboration with Dmitry I. Gabrilovich, M.D. Ph.D., a pioneer in the discovery and study of myeloid derived suppressor cells and the immune system response to cancer.

Dr. Amit Kumar, ITUS's Vice Chairman, stated, "Dr. Gabrilovich is a world renowned expert in the study of the tumor microenvironment. His research focuses on understanding the development and behavior of myeloid cells and their impact on the immune response to cancer. Dr. Gabrilovich and his colleagues were the first to coin the term Myeloid Derived Suppressor Cells (MDSCs) to describe the cells within a tumor that aid and enable the tumor in evading the body's immune response. These myeloid cells are the subject of numerous immunotherapy studies in an attempt to cure advanced cancers. Our cancer detection platform focuses on the behavior and detection of these types of cells to identify, as early as possible, patients with extant tumors. Dr. Gabrilovich's expertise will be invaluable as we enter the next phase of our clinical validation studies and seek to develop a greater understanding of these cells."

The Wistar Institute, located in Philadelphia on the campus of the University of Pennsylvania, is an international leader in biomedical research with special expertise in cancer, immunology, infectious diseases and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972, holding an 'Exceptional' rating -- the highest possible ranking awarded.

ITUS Corporation
ITUS funds, develops, acquires, and licenses emerging technologies in areas such as Biotechnology. The Company's is developing Cchek™ a platform for non-invasive, cancer screening blood tests. Additional information is available at

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our Annual Report on Form 10-K for the fiscal year ended October 31, 2015 as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.


Dean Krouch

Source: ITUS Corporation